| Developers: | CureVac |
| Branches: | Pharmaceuticals, medicine, healthcare |
Content |
Vaccines for COVID-19 coronavirus
Main article: Vaccines against COVID-19 coronavirus
2021: Vaccine effectiveness was 47% after vaccination of 40 thousand people
In mid-June 2021, the German company CureVac published preliminary results of an analysis of the effectiveness of its vaccine for coronavirus COVID-19. The manufacturer reported a low indicator, which led to a noticeable drop in its quotes.
 | The vaccine showed an intermediate efficacy of 47% against any severity of COVID-19 disease and does not meet the previously set criterion for statistical success, the CureVac said in a statement. |  |
About 40 thousand volunteers took part in clinical trials of the drug CVnCoV. CureVac clarified that the effectiveness of her drug depends on the age of patients and the strain of coronavirus.
| | Although we hoped for a more convincing intermediate result, we understand that it is extremely difficult to achieve high efficiency in such an unprecedented wide variety of options, the company noted. | |
It is noted that the study examined 134 cases of coronavirus infection that occurred at least two weeks after the introduction of the second dose of the drug. Of these, 124 cases were included in the analysis.
It turned out that more than half of the cases (57%) were caused by "options of concern," which include strains of Alpha, Beta, Gamma and Delta. The remaining cases also involved new Lambda variants found in Peru and B.1.621 from Colombia. The original strain was found in only one person. In total, 13 variants of the virus circulated in the study group, the company adds.
At the auction Germany , CureVac shares on June 17, 2021 fell by more than 52%, and the company's value decreased by almost $9.6 billion. At preliminary trading USA in shares, according to 15:48 Moscow time on June 17, 2021, cheaper by 43.88%. The main share of the shares is CureVac traded on, Nasdaq notes. Bloomberg
CureVac created the COVID-19 coronavirus vaccine together with the Paul Ehrlich Institute for Vaccine and Biomedical Medicines Development. By June 2021, clinical trials of the drug continue for almost a year.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |